A presentation at the CBI conference on exploring unexplored areas through omics analysis

2026.02.20

Researcher Satomi from the DMPK & Safety Business Unit, will deliver an oral presentation at The 471st CBI Society Lecture Meeting, to be held online.
If you plan to attend the conference, we encourage you to join the session and hear the presentation.

Conference Name: The 471st CBI Society Lecture Meeting “Creating New Opportunities for Drug Discovery through Comprehensive Omics Analyses and Informatics”

Date & Time: March 10, 2026, 16 :35 – 17:25 (JST)

Location: Online

Title: Unlocking unexplored disease biology through genomic and multi-omics analyses

Presentation Summary
Advancement in novel therapeutic modalities and AI technologies, including large language models, are expanding new opportunities to identify target candidates beyond the reach of traditional knowledge and experience.
In this presentation, we conceptualize drug target discovery as a process of exploring previously unexplored regions of disease mechanisms. We introduce a framework for interpreting disease mechanisms based on disease-associated genomic information, as well as approaches for uncovering novel mechanisms through proteomic and metabolomic analyses. We also address the challenges in advancing drug target candidates derived from data-driven approaches, including omics analyses, into practical drug discovery research.

Axcelead DDP’s Soulution
Axcelead provides an integrated end-to-end platform for multi-omics data generation and analysis, including metabolomics, proteomics, single-cell RNAseq, and spatial transcriptomics.
By leveraging Axcelead’s proprietary disease models together with publicly available genomic and omics datasets, we support a wide range of drug discovery activities, such as identification of novel therapeutic targets, drug repositioning, biomarker discovery, elucidation of mechanisms of action, and investigation of toxicity mechanisms.
Through advanced omics and bioinformatics expertise, we propose tailored solutions to challenges in drug discovery research. Please feel free to contact us for further discussion.

Related Service: Omics, Bioinformatics